{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:18:38Z","timestamp":1775071118867,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Region Occitanie\/Pyr\u00e9n\u00e9es-M\u00e9diterran\u00e9e","award":["1901175"],"award-info":[{"award-number":["1901175"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["MP0022856"],"award-info":[{"award-number":["MP0022856"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimer Prevention in Occitania and Catalonia"},{"DOI":"10.13039\/100010390","name":"Saint Louis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010390","id-type":"DOI","asserted-by":"publisher"}]},{"name":"G\u00e9rontop\u00f4le of Toulouse"},{"name":"French Ministry of Health"},{"DOI":"10.13039\/100020910","name":"Pierre Fabre Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020910","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ExonHit Therapeutics SA"},{"name":"Avid Radiopharmaceuticals Inc"},{"DOI":"10.13039\/501100006556","name":"University Hospital Center of Toulouse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006556","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Monegasque pour la Recherche sur la maladie d\u2019Alzheimer"},{"name":"INSERM-University of Toulouse III UMR 1295 (CERPOP) Research Unit"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intrinsic capacity (IC) is a concept related to functionality that reflects healthy aging. ATPase inhibitory factor 1 (IF1) is a multifaceted protein that regulates mitochondrial oxidative phosphorylation (OXPHOS), and may be involved in IC. The objective of this study is to investigate the association between plasma levels of IF1 and IC changes in community-dwelling older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Community-dwelling older adults from the Multidomain Alzheimer Preventive Trial (MAPT Study) were enrolled in this study. A composite IC score was calculated based on 4 IC domains: locomotion, psychological dimension, cognition, and vitality (with data available annually over 4 years of follow-up). Secondary analyses were conducted on the sensory domain (with data available only for 1 year of follow-up). Mixed-model linear regression adjusted for confounders was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1 090 participants with usable IF1 values were included in the study (75.3 \u00b1 4.4 years; 64% females). Compared to the lowest quartile, both the low\u2013 and high\u2013intermediate IF1 quartiles were found to be cross-sectionally associated with greater composite IC scores across 4 domains (\u03b2low\u2013intermediate, 1.33; 95% confidence interval [CI] 0.06\u20132.60 and \u03b2high\u2013intermediate, 1.78; 95% CI 0.49\u20133.06). In the secondary analyses, the highest quartile was found to be associated with a slower decline in composite IC scores across 5 domains over 1 year (\u03b2high 1.60; 95% CI 0.06\u20133.15). The low\u2013 and high\u2013intermediate IF1 quartiles were also found to be cross-sectionally associated with greater locomotion (\u03b2low\u2013intermediate, 2.72; 95% CI 0.36\u20135.08) and vitality scores (\u03b2high\u2013intermediate, 1.59; 95% CI 0.06\u20133.12), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study is the first to demonstrate that levels of circulating IF1, a mitochondrial-related biomarker, are associated with IC composite scores in both cross-sectional and prospective analyses among community-dwelling older adults. However, further research is needed to confirm these findings and elucidate the potential underlying mechanisms that may explain these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gerona\/glad142","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T05:40:49Z","timestamp":1685770849000},"source":"Crossref","is-referenced-by-count":3,"title":["Plasma Level of ATPase Inhibitory Factor 1 and Intrinsic Capacity in Community-Dwelling Older Adults: Prospective Data From the MAPT Study"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-9073","authenticated-orcid":false,"given":"Jaqueline Aragoni","family":"da Silva","sequence":"first","affiliation":[{"name":"Institut du Vieillissement, G\u00e9rontop\u00f4le de Toulouse, Centre Hospitalo-Universitaire de Toulouse , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-3152","authenticated-orcid":false,"given":"Laurent O","family":"Martinez","sequence":"additional","affiliation":[{"name":"LiMitAging, Institut des Maladies M\u00e9taboliques et Cardiovasculaires, I2MC, Universit\u00e9 de Toulouse, INSERM, Universit\u00e9 Toulouse III - Paul Sabatier (UPS) , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-0215","authenticated-orcid":false,"given":"Yves","family":"Rolland","sequence":"additional","affiliation":[{"name":"Institut du Vieillissement, G\u00e9rontop\u00f4le de Toulouse, Centre Hospitalo-Universitaire de Toulouse , Toulouse , France"},{"name":"CERPOP UMR 1295, University of Toulouse III, INSERM, UPS , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5509-1411","authenticated-orcid":false,"given":"Souad","family":"Najib","sequence":"additional","affiliation":[{"name":"LiMitAging, Institut des Maladies M\u00e9taboliques et Cardiovasculaires, I2MC, Universit\u00e9 de Toulouse, INSERM, Universit\u00e9 Toulouse III - Paul Sabatier (UPS) , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-5817","authenticated-orcid":false,"given":"Mika\u00ebl","family":"Croyal","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, CNRS, INSERM, l\u2019institut du Thorax, BioCore, US16, SFR Bonamy , F-44000 Nantes , France"},{"name":"CRNH-Ouest Mass Spectrometry Core Facility , Nantes , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-445X","authenticated-orcid":false,"given":"Bertrand","family":"Perret","sequence":"additional","affiliation":[{"name":"LiMitAging, Institut des Maladies M\u00e9taboliques et Cardiovasculaires, I2MC, Universit\u00e9 de Toulouse, INSERM, Universit\u00e9 Toulouse III - Paul Sabatier (UPS) , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-7836","authenticated-orcid":false,"given":"Nabila","family":"Jabrane-Ferrat","sequence":"additional","affiliation":[{"name":"Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM-CNRS-University Toulouse III , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-9759","authenticated-orcid":false,"given":"Hicham","family":"El Costa","sequence":"additional","affiliation":[{"name":"Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM-CNRS-University Toulouse III , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9527-5282","authenticated-orcid":false,"given":"Sophie","family":"Guyonnet","sequence":"additional","affiliation":[{"name":"Institut du Vieillissement, G\u00e9rontop\u00f4le de Toulouse, Centre Hospitalo-Universitaire de Toulouse , Toulouse , France"},{"name":"CERPOP UMR 1295, University of Toulouse III, INSERM, UPS , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7678-5065","authenticated-orcid":false,"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[{"name":"Institut du Vieillissement, G\u00e9rontop\u00f4le de Toulouse, Centre Hospitalo-Universitaire de Toulouse , Toulouse , France"},{"name":"CERPOP UMR 1295, University of Toulouse III, INSERM, UPS , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-425X","authenticated-orcid":false,"given":"Philipe","family":"de Souto Barreto","sequence":"additional","affiliation":[{"name":"Institut du Vieillissement, G\u00e9rontop\u00f4le de Toulouse, Centre Hospitalo-Universitaire de Toulouse , Toulouse , France"},{"name":"CERPOP UMR 1295, University of Toulouse III, INSERM, UPS , Toulouse , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the MAPT\/DSA group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2023122103445034100_CIT0001","author":"World Health Organization.","year":"2015"},{"key":"2023122103445034100_CIT0002","first-page":"2","article-title":"Operationalising the concept of intrinsic capacity in clinical settings","author":"de Carvalho","year":"2017"},{"issue":"5","key":"2023122103445034100_CIT0003","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/gerona\/glac227","article-title":"Mitochondrial dysfunction and intrinsic capacity: insights from a narrative review","volume":"78","author":"Silva","year":"2023","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"2023122103445034100_CIT0004","volume-title":"Biologia Molecular da C\u00e9lula.","author":"Alberts","year":"2017"},{"issue":"6","key":"2023122103445034100_CIT0005","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell."},{"issue":"5","key":"2023122103445034100_CIT0006","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.molcel.2016.01.028","article-title":"The mitochondrial basis of aging","volume":"61","author":"Sun","year":"2016","journal-title":"Mol Cell."},{"issue":"4-6","key":"2023122103445034100_CIT0007","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/ars.2021.0137","article-title":"The multifaceted ATPase inhibitory factor 1 (IF1) in energy metabolism reprogramming and mitochondrial dysfunction: a new player in age-associated disorders?","volume":"37","author":"Gore","year":"2022","journal-title":"Antioxid Redox Signal."},{"key":"2023122103445034100_CIT0008","doi-asserted-by":"crossref","first-page":"917203","DOI":"10.3389\/fphys.2022.917203","article-title":"The F1Fo-ATPase inhibitor protein IF1 in pathophysiology","volume":"13","author":"Gatto","year":"2022","journal-title":"Front Physiol."},{"issue":"1","key":"2023122103445034100_CIT0009","doi-asserted-by":"crossref","first-page":"101391","DOI":"10.1016\/j.diabet.2022.101391","article-title":"Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: a prospective cohort stud","volume":"49","author":"Silva","year":"2023","journal-title":"Diabetes Metab."},{"issue":"2","key":"2023122103445034100_CIT0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.7150\/ijbs.64956","article-title":"ATPase inhibitory factor 1 protects the heart from acute myocardial ischemia\/reperfusion injury through activating AMPK signaling pathway","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci."},{"issue":"10","key":"2023122103445034100_CIT0011","doi-asserted-by":"crossref","first-page":"e155333","DOI":"10.1172\/JCI155333","article-title":"Upregulation of mitochondrial ATPase inhibitory factor 1 (ATPIF1) mediates increased glycolysis in mouse hearts","volume":"132","author":"Zhou","year":"2022","journal-title":"J Clin Invest."},{"issue":"9","key":"2023122103445034100_CIT0012","doi-asserted-by":"crossref","first-page":"e23949","DOI":"10.1371\/journal.pone.0023949","article-title":"Mitochondrial inhibitory factor 1 (IF1) is present in human serum and is positively correlated with HDL-cholesterol","volume":"6","author":"Genoux","year":"2011","journal-title":"PLoS One."},{"issue":"1","key":"2023122103445034100_CIT0013","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12916-016-0672-9","article-title":"Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study","volume":"14","author":"Genoux","year":"2016","journal-title":"BMC Med."},{"issue":"9","key":"2023122103445034100_CIT0014","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1194\/jlr.P036335","article-title":"Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study","volume":"54","author":"Genoux","year":"2013","journal-title":"J Lipid Res."},{"issue":"1","key":"2023122103445034100_CIT0015","first-page":"13","article-title":"MAPT Study: a multidomain approach for preventing Alzheimer\u2019s disease: design and baseline data","volume":"1","author":"Vellas","year":"2014","journal-title":"J Prev Alz Dis."},{"key":"2023122103445034100_CIT0016","doi-asserted-by":"crossref","first-page":"121300","DOI":"10.1016\/j.talanta.2020.121300","article-title":"A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS\/MS: comparison with conventional ELISA","volume":"219","author":"Genoux","year":"2020","journal-title":"Talanta"},{"issue":"2","key":"2023122103445034100_CIT0017","doi-asserted-by":"crossref","first-page":"M85","DOI":"10.1093\/geronj\/49.2.M85","article-title":"A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission","volume":"49","author":"Guralnik","year":"1994","journal-title":"J Gerontol"},{"issue":"1\u20132","key":"2023122103445034100_CIT0018","first-page":"165","article-title":"Geriatric Depression Scale (GDS). recent evidence and development of a shorter version","volume":"5","author":"Sheikh","year":"1986","journal-title":"Clin Gerontol"},{"issue":"3","key":"2023122103445034100_CIT0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state.\u201d A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res."},{"issue":"9","key":"2023122103445034100_CIT0020","first-page":"959","article-title":"WHO Clinical Consortium on Healthy Ageing 2017\u2014report of consortium meeting","volume":"24","author":"World Health Organization","year":"2017","journal-title":"J Nutr Health Aging"},{"issue":"3","key":"2023122103445034100_CIT0021","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00003446-198205000-00006","article-title":"The hearing handicap inventory for the elderly: a new tool","volume":"3","author":"Ventry","year":"1982","journal-title":"Ear Hear."},{"key":"2023122103445034100_CIT0022","volume-title":"Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee.","author":"World Health Organization.","year":"1995"},{"key":"2023122103445034100_CIT0023","article-title":"Fitting Linear Mixed-Effects Models using lme4.","volume-title":"arXiv:14065823 [stat]","author":"Bates","year":"2014"},{"issue":"1","key":"2023122103445034100_CIT0024","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.6357","article-title":"Down-regulation of oxidative phosphorylation in the liver by expression of the ATPase inhibitory factor 1 induces a tumor-promoter metabolic state","volume":"7","author":"Santacatterina","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2023122103445034100_CIT0025","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/s41598-020-58411-x","article-title":"Overexpression of native IF1 downregulates glucose-stimulated insulin secretion by pancreatic INS-1E cells","volume":"10","author":"Kahancov\u00e1","year":"2020","journal-title":"Sci Rep."},{"issue":"10","key":"2023122103445034100_CIT0026","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s00125-017-4379-z","article-title":"Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance","volume":"60","author":"Formentini","year":"2017","journal-title":"Diabetologia."},{"issue":"5","key":"2023122103445034100_CIT0027","doi-asserted-by":"crossref","first-page":"e3001252","DOI":"10.1371\/journal.pbio.3001252","article-title":"Generation of mitochondrial reactive oxygen species is controlled by ATPase inhibitory factor 1 and regulates cognition","volume":"19","author":"Esparza-Molt\u00f3","year":"2021","journal-title":"PLoS Biol."},{"issue":"1","key":"2023122103445034100_CIT0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10522-013-9475-y","article-title":"The role of mitochondria in age-related hearing loss","volume":"15","author":"Chen","year":"2014","journal-title":"Biogerontology"},{"issue":"6","key":"2023122103445034100_CIT0029","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2012.01.008","article-title":"The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response","volume":"45","author":"Formentini","year":"2012","journal-title":"Mol Cell."},{"issue":"22","key":"2023122103445034100_CIT0030","doi-asserted-by":"crossref","first-page":"18781","DOI":"10.1074\/jbc.M112.345793","article-title":"Assessing actual contribution of IF1, inhibitor of mitochondrial FoF1, to ATP homeostasis, cell growth, mitochondrial morphology, and cell viability","volume":"287","author":"Fujikawa","year":"2012","journal-title":"J Biol Chem."},{"issue":"3","key":"2023122103445034100_CIT0031","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s43587-022-00189-w","article-title":"The energy\u2013splicing resilience axis hypothesis of aging","volume":"2","author":"Ferrucci","year":"2022","journal-title":"Nat Aging"},{"issue":"12","key":"2023122103445034100_CIT0032","doi-asserted-by":"crossref","first-page":"14825","DOI":"10.1096\/fj.201901440RR","article-title":"ATP synthase inhibitory factor 1 (IF1), a novel myokine, regulates glucose metabolism by AMPK and Akt dual pathways","volume":"33","author":"Lee","year":"2019","journal-title":"FASEB J."},{"issue":"6","key":"2023122103445034100_CIT0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0578-x","article-title":"Reduction of the \u00adATPase inhibitory factor 1 (IF1) leads to visual impairment in vertebrates","volume":"9","author":"Mart\u00edn-Jim\u00e9nez","year":"2018","journal-title":"Cell Death Dis."},{"key":"2023122103445034100_CIT0034","doi-asserted-by":"crossref","first-page":"868820","DOI":"10.3389\/fphys.2022.868820","article-title":"The ATPase inhibitory factor 1 is a tissue-specific physiological regulator of the structure and function of mitochondrial ATP synthase: a closer look into neuronal function","volume":"13","author":"Dom\u00ednguez-Zorita","year":"2022","journal-title":"Front Physiol."},{"issue":"1","key":"2023122103445034100_CIT0035","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1038\/s41598-022-07851-8","article-title":"Neuroprotective effects of ATPase inhibitory factor 1 preventing mitochondrial dysfunction in Parkinson\u2019s disease","volume":"12","author":"Chung","year":"2022","journal-title":"Sci Rep."}],"container-title":["The Journals of Gerontology: Series A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/advance-article-pdf\/doi\/10.1093\/gerona\/glad142\/50888143\/glad142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/79\/1\/glad142\/54705370\/glad142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/79\/1\/glad142\/54705370\/glad142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T22:45:51Z","timestamp":1703112351000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article\/doi\/10.1093\/gerona\/glad142\/7191210"}},"subtitle":[],"editor":[{"given":"Roger","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/gerona\/glad142","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.02.22279534","asserted-by":"object"}]},"ISSN":["1079-5006","1758-535X"],"issn-type":[{"value":"1079-5006","type":"print"},{"value":"1758-535X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2023,6,7]]},"article-number":"glad142"}}